The proposed dual targeting strategy can drastically enhance anticancer therapy of HER2-positive cells, which made possible a 1000-fold decrease in the effective drug concentration in vitro and a significant enhancement of HER2 cancer therapy compared to monotherapy in vivo. This evidence concerns the gene ERBB2 and cancer.